Issue

Vol. 64 No. 6: Advances in mechanism and treatment strategy of cancer

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Levels of serum bilirubin in small cell lung cancer and non-small cell lung cancer patients

https://doi.org/10.14715/cmb/2018.64.6.13
Da Jiang
Department of Medical Oncology, Forth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang 050011, Hebei, China
Jian Shi
Department of Medical Oncology, Forth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang 050011, Hebei, China
Meng Yuan
Department of Clinical Medicine, College of Science Technology of China Three Gorges University, Yichang 443000, Hubei, China
Xiaoyang Duan
Department of Medical Oncology, Forth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang 050011, Hebei, China
Lihua Li
Department of Medical Oncology, Forth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang 050011, Hebei, China
Qian Li
Department of Radiotherapy, Cangzhou hosptial of Integrated TCM-WM, Cangzhou 061001, Hebei, China

Corresponding Author(s) : Jian Shi

shijian6668@126.com

Cellular and Molecular Biology, Vol. 64 No. 6: Advances in mechanism and treatment strategy of cancer

Abstract

Elevated bilirubin has been associated with protection of cardiovascular and kidney systems, whereas decreased bilirubin may predispose respiratory diseases. However, whether serum bilirubin levels are associated with lung cancer remains unclear. Here, clinical and pathologic data of a cohort of 363 lung cancer patients along with 363 age-and gender-matched healthy subjects were collected. The association of serum bilirubin levels with lung cancer was analyzed. The levels of serum bilirubin were significantly lower in lung cancer patients. The aspartate transaminase and alkaline phosphatase levels were significantly higher in lung cancer. Multi-classification logistics regression analysis revealed low total bilirubin level [OR (95%CI), 1.12 (1.02-1.23)], aspartate transaminase [OR (95%CI), 1.12 (1.02-1.23)], and alanine transaminase [OR (95%CI), 1.12 (1.02-1.23)] were risk factors in lung cancer. Serum bilirubin levels were significantly changed among small cell lung cancer (SCLC), lung adenocarcinoma (LAC) and lung squamous cell carcinoma (LSC). Total bilirubin level, smoke history and heart disease were risk factors for subtypes. Compared with LSC, patients with smoke history had significant higher risk in LAC [OR (95% Confidence Interval, CI), 4.49 (1.70, 11.96)]. Compared with LSC, patients with smoke history [OR (95%CI), 4.49 (1.70, 11.96)] and heart disease [OR (95%CI), 4.49 (1.70, 11.96)] had significant higher risk in SCLC. Compared with SCLC, patients with low total bilirubin [OR (95%CI), 1.12 (1.02-1.23)] and heart disease [OR (95%CI), 3.52 (1.01-12.23)] had significant higher risk in LAC. Taken together, these results suggested low serum bilirubin levels are tightly associated with lung cancer, especially with LAC. Serum bilirubin levels might serve as a predictor for lung cancer patients clinically.

Keywords

Bilirubin Small cell lung cancer Non-small lung cancer Lung adenocarcinoma Lung squamous cell carcinoma.
Jiang, D., Shi, J., Yuan, M., Duan, X., Li, L., & Li, Q. (2018). Levels of serum bilirubin in small cell lung cancer and non-small cell lung cancer patients. Cellular and Molecular Biology, 64(6), 71–76. https://doi.org/10.14715/cmb/2018.64.6.13
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Yarmus L, Nguyen PT, Montemayor K et al. Year in review 2017: Interventional pulmonology, lung cancer, pleural disease and respiratory infections. Respirology (Carlton, Vic) Apr 11 2018.
  2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a cancer journal for clinicians Jan 2017; 67(1): 7-30.
  3. Shroff GS, Viswanathan C, Carter BW, Benveniste MF, Truong MT, Sabloff BS. Staging Lung Cancer: Metastasis. Radiologic clinics of North America May 2018; 56(3): 411-418.
  4. Shroff GS, de Groot PM, Papadimitrakopoulou VA, Truong MT, Carter BW. Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer. Radiologic clinics of North America May 2018; 56(3): 485-495.
  5. Ciliberto M, Kishida Y, Seki S, Yoshikawa T, Ohno Y. Update of MR Imaging for Evaluation of Lung Cancer. Radiologic clinics of North America May 2018; 56(3): 437-469.
  6. Benveniste MF, Welsh J, Viswanathan C et al. Lung Cancer: Posttreatment Imaging: Radiation Therapy and Imaging Findings. Radiologic clinics of North America May 2018; 56(3): 471-483.
  7. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Seminars in interventional radiology Jun 2013; 30(2): 93-98.
  8. Chen X, Mao G, Chen H et al. TW37 enhances the pro-apoptosis and anti-migration ability of gefitinib in Non-Small Cell Lung Cancer. Cellular and molecular biology (Noisy-le-Grand, France) Mar 31 2018; 64(4): 6-10.
  9. Ramakrishnan N, Jialal I. Bilirubin, Impaired Conjugation. StatPearls. Treasure Island (FL): StatPearls Publishing; 2018.
  10. Kalakonda A, John S. Physiology, Bilirubin. StatPearls. Treasure Island (FL): StatPearls Publishing; 2018.
  11. Holbrook I, Beetham R, Cruickshank A et al. National audit of cerebrospinal fluid testing. Annals of clinical biochemistry Sep 2007; 44(Pt 5): 443-448.
  12. Beetham R, Egner W, Patel D. The UKNEQAS scheme for cerebrospinal fluid haem pigments: a paradigm for service improvement. Annals of clinical biochemistry Nov 2011; 48(Pt 6): 489-497.
  13. Vitek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Frontiers in pharmacology 2012; 3: 55.
  14. Ryu S, Chang Y, Zhang Y et al. Higher serum direct bilirubin levels were associated with a lower risk of incident chronic kidney disease in middle aged Korean men. PloS one 2014; 9(2): e75178.
  15. Horsfall LJ, Rait G, Walters K et al. Serum bilirubin and risk of respiratory disease and death. Jama 2011; 305(7): 691.
  16. Hamoud AR, Weaver L, Stec DE, Hinds TD, Jr. Bilirubin in the Liver-Gut Signaling Axis. Trends in endocrinology and metabolism: TEM Mar 2018; 29(3): 140-150.
  17. Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Advances in clinical chemistry 2007; 43: 1-57.
  18. Ryter SW, Morse D, Choi AM. Carbon monoxide and bilirubin: potential therapies for pulmonary/vascular injury and disease. American journal of respiratory cell and molecular biology Feb 2007; 36(2): 175-182.
  19. Nakagami T, Toyomura K, Kinoshita T, Morisawa S. A beneficial role of bile pigments as an endogenous tissue protector: anti-complement effects of biliverdin and conjugated bilirubin. Biochimica et biophysica acta Oct 3 1993; 1158(2): 189-193.
  20. Zeng Y. Cell biology, biophysics, and mechanobiology: From the basics to Clinics. Cell Mol Biol (Noisy-le-grand) Apr 29 2017; 63(4): 1-2.
  21. Zhang H, Li G, Zhu Z et al. Serum bilirubin level predicts postoperative overall survival in oral squamous cell carcinoma. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology Feb 11 2018.
  22. Li XH, Lin HY, Guan LY et al. Direct Bilirubin Levels and Risk of Metabolic Syndrome in Healthy Chinese Men. Biomed Res Int 2017; 2017: 9621615.
  23. Li WC, Mo LJ, Shi X et al. Antioxidant status of serum bilirubin, uric acid and albumin in pemphigus vulgaris. Clinical and experimental dermatology Mar 2018; 43(2): 158-163.
  24. Chen J, Wang J, Zhang X, Zhu H. Inverse Relationship Between Serum Bilirubin Levels and Diabetic Foot in Chinese Patients with Type 2 Diabetes Mellitus. Medical science monitor : international medical journal of experimental and clinical research Dec 14 2017; 23: 5916-5923.
  25. Jin J, Wang W, Gu T et al. Low serum bilirubin levels contribute to the presence and progression of distal symmetrical polyneuropathy in Chinese patients with type 2 diabetes. Diabetes & metabolism Feb 22 2018.
  26. Bissell MG. Serum Bilirubin and Risk of Respiratory Disease and Death. Yearbook of Pathology & Laboratory Medicine 2012; 2012: 283-284.
  27. Endler G, Hamwi A, Sunderplassmann R et al. Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women? Clinical Chemistry 2003; 49(7): 1201-1204.
  28. Kim DW, Kim KC, Kim KB, Dunn CT, Park KS. Transcriptional deregulation underlying the pathogenesis of small cell lung cancer. Translational lung cancer research Feb 2018; 7(1): 4-20.
  29. Basumallik N, Agarwal M. Cancer, Lung, Small Cell (Oat Cell). StatPearls. Treasure Island (FL): StatPearls Publishing; 2018.
  30. Rosenthal P, Pincus M, Fink D. Sex- and age-related differences in bilirubin concentrations in serum. Clinical chemistry Aug 1984; 30(8): 1380-1382.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 1008 Download : 490